| Symbol | REPL |
|---|---|
| Name | REPLIMUNE GROUP, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 500 UNICORN PARK,3RD FLOOR, WOBURN, Massachusetts, 01801, United States |
| Telephone | +1 781 222-9600 |
| Fax | — |
| — | |
| Website | https://www.replimune.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001737953 |
| Description | Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. Additional info from NASDAQ: |
New Form S-3ASR - Replimune Group, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097309 <b>Size:</b> 1 MB
Read more(10% Negative) REPLIMUNE GROUP, INC. (REPL) Reports Q3 2026 Financial Results
Read moreReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Read moreINVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL
Read moreSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
Read moreBronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Read moreREPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Read moreINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Read moreDirector Patel Sushil 🔴 sold 39.3K shares of Replimune Group, Inc. (REPL) at $12.97 Transaction Date: Aug 10, 2026 | Filing ID: 095012
Read moreHill Emily Luisa 🔴 sold 11.4K shares of Replimune Group, Inc. (REPL) at $12.97 Transaction Date: Aug 10, 2026 | Filing ID: 095008
Read more